{
    "organizations": [],
    "uuid": "9f93b7a3097b9519c5676039ac4d3ee9c08f813b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alkermes-submits-nda-to-us-fda-for/brief-alkermes-submits-nda-to-u-s-fda-for-alks-5461-for-adjunctive-treatment-of-major-depressive-disorder-idUSASB0C3AQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Alkermes Submits NDA To U.S. FDA For ALKS 5461 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 31, 2018 / 7:34 PM / Updated 24 minutes ago BRIEF-Alkermes Submits NDA To U.S. FDA For ALKS 5461 FOR ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER Reuters Staff 1 Min Read \nJan 31 (Reuters) - Alkermes Plc: \n* ALKERMES SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER Source text for Eikon: Further company coverage:",
    "published": "2018-01-31T21:31:00.000+02:00",
    "crawled": "2018-01-31T22:07:51.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "submits",
        "nda",
        "fda",
        "alks",
        "adjunctive",
        "treatment",
        "major",
        "depressive",
        "disorder",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "alkermes",
        "plc",
        "alkermes",
        "submits",
        "new",
        "drug",
        "application",
        "fda",
        "alks",
        "adjunctive",
        "treatment",
        "major",
        "depressive",
        "disorder",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}